View Item 

Show simple item record

Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
dc.contributor.authorAgustí, Alvar
dc.contributor.authorCelli, Bartolome R.
dc.contributor.authorCriner, Gerard J.
dc.contributor.authorHalpin, David
dc.contributor.authorAnzueto, Antonio
dc.contributor.authorBarnes, Peter
dc.contributor.authorBourbeau, Jean
dc.contributor.authorHan, MeiLan K.
dc.contributor.authorMartinez, Fernando J.
dc.contributor.authorOca, Maria Montes
dc.contributor.authorMortimer, Kevin
dc.contributor.authorPapi, Alberto
dc.contributor.authorPavord, Ian
dc.contributor.authorRoche, Nicolas
dc.contributor.authorSalvi, Sundeep
dc.contributor.authorSin, Don D.
dc.contributor.authorSingh, Dave
dc.contributor.authorStockley, Robert
dc.contributor.authorVarela, M. Victorina López
dc.contributor.authorWedzicha, Jadwiga A.
dc.contributor.authorVogelmeier, Claus F.
dc.date.accessioned2023-04-04T17:41:12Z
dc.date.available2024-05-04 13:41:10en
dc.date.available2023-04-04T17:41:12Z
dc.date.issued2023-04
dc.identifier.citationAgustí, Alvar ; Celli, Bartolome R.; Criner, Gerard J.; Halpin, David; Anzueto, Antonio; Barnes, Peter; Bourbeau, Jean; Han, MeiLan K.; Martinez, Fernando J.; Oca, Maria Montes; Mortimer, Kevin; Papi, Alberto; Pavord, Ian; Roche, Nicolas; Salvi, Sundeep; Sin, Don D.; Singh, Dave; Stockley, Robert; Varela, M. Victorina López ; Wedzicha, Jadwiga A.; Vogelmeier, Claus F. (2023). "Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary." Respirology 28(4): 316-338.
dc.identifier.issn1323-7799
dc.identifier.issn1440-1843
dc.identifier.urihttps://hdl.handle.net/2027.42/176060
dc.publisherJohn Wiley & Sons, Ltd
dc.titleGlobal Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176060/1/resp14486.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176060/2/resp14486_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176060/3/resp14486-sup-0001-Supinfo.pdf
dc.identifier.doi10.1111/resp.14486
dc.identifier.sourceRespirology
dc.identifier.citedreferenceXia J, Gu S, Lei W, Zhang J, Wei H, Liu C, et al. High-flow nasal cannula versus conventional oxygen therapy in acute COPD exacerbation with mild hypercapnia: a multicenter randomized controlled trial. Crit Care. 2022; 26: 109.
dc.identifier.citedreferencede Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease: Incidence and Predicting Factors. Am J Respir Crit Care Med. 2011; 184: 913 – 9.
dc.identifier.citedreferenceHuang JT-J, Cant E, Keir HR, Barton AK, Kuzmanova E, Shuttleworth M, et al. Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the “Chronic Obstructive Pulmonary Disease–Bronchiectasis Association”. Am J Respir Crit Care Med. 2022; 206: 417 – 26.
dc.identifier.citedreferenceSoler X, Gaio E, Powell FL, Ramsdell JW, Loredo JS, Malhotra A, et al. High Prevalence of Obstructive Sleep Apnea in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2015; 12: 1219 – 25.
dc.identifier.citedreferenceJorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med. 2007; 101: 177 – 85.
dc.identifier.citedreferenceCebron Lipovec N, Beijers RJHCG, van den Borst B, Doehner W, Lainscak M, Schols AMWJ. The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. COPD: J Chron Obstruct Pulmon Dis. 2016; 13: 399 – 406.
dc.identifier.citedreferenceHurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. 2010; 363: 1128 – 38.
dc.identifier.citedreferenceIngebrigtsen TS, Marott JL, Vestbo J, Nordestgaard BG, Hallas J, Lange P. Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology. 2015; 20: 101 – 7.
dc.identifier.citedreferenceSasaki T, Nakayama K, Yasuda H, Yoshida M, Asamura T, Ohrui T, et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc. 2009; 57: 1453 – 7.
dc.identifier.citedreferenceBaumeler L, Papakonstantinou E, Milenkovic B, Lacoma A, Louis R, Aerts JG, et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology. 2016; 21: 883 – 90.
dc.identifier.citedreferencePutcha N, Fawzy A, Paul GG, Lambert AA, Psoter KJ, Sidhaye VK, et al. Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS. Ann Am Thorac Soc. 2018; 15: 710 – 7.
dc.identifier.citedreferenceNakamura A, Kasamatsu N, Hashizume I, Shirai T, Hanzawa S, Momiki S, et al. Effects of hemoglobin on pulmonary arterial pressure and pulmonary vascular resistance in patients with chronic emphysema. Respiration. 2000; 67: 502 – 6.
dc.identifier.citedreferenceSamareh Fekri M, Torabi M, Azizi Shoul S, Mirzaee M. Prevalence and predictors associated with severe pulmonary hypertension in COPD. Am J Emerg Med. 2018; 36: 277 – 80.
dc.identifier.citedreferenceKent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J Chron Obstruct Pulmon Dis. 2011; 6: 199 – 208.
dc.identifier.citedreferenceChambellan A, Chailleux E, Similowski T, Group AO. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest. 2005; 128: 1201 – 8.
dc.identifier.citedreferenceHanania NA, Mullerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011; 183: 604 – 11.
dc.identifier.citedreferenceKunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005; 127: 1205 – 11.
dc.identifier.citedreferenceNg TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007; 167: 60 – 7.
dc.identifier.citedreferenceMaurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008; 134: 43S – 56S.
dc.identifier.citedreferenceEisner MD, Blanc PD, Yelin EH, Katz PP, Sanchez G, Iribarren C, et al. Influence of anxiety on health outcomes in COPD. Thorax. 2010; 65: 229 – 34.
dc.identifier.citedreferenceChen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015; 3: 631 – 9.
dc.identifier.citedreferenceCleutjens FA, Franssen FM, Spruit MA, Vanfleteren LE, Gijsen C, Dijkstra JB, et al. Domain-specific cognitive impairment in patients with COPD and control subjects. Int J Chron Obstruct Pulmon Dis. 2017; 12: 1 – 11.
dc.identifier.citedreferenceCleutjens F, Spruit MA, Ponds R, Vanfleteren L, Franssen FME, Gijsen C, et al. Cognitive impairment and clinical characteristics in patients with chronic obstructive pulmonary disease. Chron Respir Dis. 2018; 15: 91 – 102.
dc.identifier.citedreferenceFried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56: M146 – 56.
dc.identifier.citedreferenceTalic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. BMJ. 2021; 375: e068302.
dc.identifier.citedreferenceHalpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 & COPD. Am J Respir Crit Care Med. 2021; 203: 24 – 36.
dc.identifier.citedreferenceAlqahtani JS, Oyelade T, Aldhahir AM, Mendes RG, Alghamdi SM, Miravitlles M, et al. Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis. PLoS One. 2021; 16: e0255659.
dc.identifier.citedreferenceHalpin DMG, Rabe AP, Loke WJ, Grieve S, Daniele P, Hwang S, et al. Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: A Systematic Literature Review and Meta-Analyses. J Asthma Allergy. 2022; 15: 811 – 25.
dc.identifier.citedreferenceLipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients. Am J Respir Crit Care Med. 2020; 201: 1508 – 16.
dc.identifier.citedreferenceAnthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005; 142: 233 – 9.
dc.identifier.citedreferenceRyrsø CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med. 2018; 18: 154.
dc.identifier.citedreferenceGroup. NOTT. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. A clinical trial. Ann Intern Med. 1980; 93: 391 – 8.
dc.identifier.citedreferenceParty RotMRCW. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981; i: 681 – 5.
dc.identifier.citedreferenceKohnlein T, Windisch W, Kohler D, Drabik A, Geiseler J, Hartl S, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2014; 2: 698 – 705.
dc.identifier.citedreferenceGroup NETTR. A Randomized Trial Comparing Lung-Volume-Reduction Surgery with Medical Therapy for Severe Emphysema. N Engl J Med. 2003; 348: 2059 – 73.
dc.identifier.citedreferenceGlobal Initiative for Chronic Obstructive Lung Disease (GOLD). 2023. Available from: https://goldcopd.org/2023-gold-report-2/.
dc.identifier.citedreferenceCelli B, Fabbri L, Criner G, Martinez FJ, Mannino D, Vogelmeier C, et al. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision. Am J Respir Crit Care Med. 2022; 206: 1317 – 25.
dc.identifier.citedreferenceGlobal Initiative for Chronic Obstructive Lung Disease. 2022. Available from: www.goldcopd.org.
dc.identifier.citedreferenceAgustí A, Melén E, DeMeo DL, Breyer-Kohansal R, Faner R. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan. Lancet Respir Med. 2022; 10: 512 – 24.
dc.identifier.citedreferenceKohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The Natural History of Chronic Airflow Obstruction Revisited: An Analysis of the Framingham Offspring Cohort. Am J Respir Crit Care Med. 2009; 180: 3 – 10.
dc.identifier.citedreferenceRennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet. 2006; 367: 1216 – 9.
dc.identifier.citedreferenceRaad D, Gaddam S, Schunemann HJ, Irani J, Abou Jaoude P, Honeine R, et al. Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. Chest. 2011; 139: 764 – 74.
dc.identifier.citedreferenceGünen H, Tarraf H, Nemati A, Al Ghobain M, Al Mutairi S, Aoun Bacha Z. Waterpipe tobacco smoking. Tuberkuloz ve toraks. 2016; 64: 94 – 6.
dc.identifier.citedreferenceShe J, Yang P, Wang Y, Qin X, Fan J, Wang Y, et al. Chinese water-pipe smoking and the risk of COPD. Chest. 2014; 146: 924 – 31.
dc.identifier.citedreferenceTan WC, Lo C, Jong A, Xing L, Fitzgerald MJ, Vollmer WM, et al. Marijuana and chronic obstructive lung disease: a population-based study. Cmaj. 2009; 180: 814 – 20.
dc.identifier.citedreferenceYin P, Jiang CQ, Cheng KK, Lam TH, Lam KH, Miller MR, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet. 2007; 370: 751 – 7.
dc.identifier.citedreferenceTager IB, Ngo L, Hanrahan JP. Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. Am J Respir Crit Care Med. 1995; 152: 977 – 83.
dc.identifier.citedreferenceYang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med. 2022; 10: 497 – 511.
dc.identifier.citedreferenceOrozco-Levi M, Garcia-Aymerich J, Villar J, Ramírez-Sarmiento A, Antó JM, Gea J. Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J. 2006; 27: 542 – 6.
dc.identifier.citedreferenceMortimer K, Montes de Oca M, Salvi S, Balakrishnan K, Hadfield RM, Ramirez-Venegas A, et al. Household air pollution and COPD: cause and effect or confounding by other aspects of poverty? Int J Tuberc Lung Dis. 2022; 26: 206 – 16.
dc.identifier.citedreferenceSana A, Somda SMA, Meda N, Bouland C. Chronic obstructive pulmonary disease associated with biomass fuel use in women: a systematic review and meta-analysis. BMJ Open Respir Res. 2018; 5: e000246.
dc.identifier.citedreferenceRamírez-Venegas A, Montiel-Lopez F, Falfan-Valencia R, Pérez-Rubio G, Sansores RH. The "Slow Horse Racing Effect" on Lung Function in Adult Life in Chronic Obstructive Pulmonary Disease Associated to Biomass Exposure. Front Med (Lausanne). 2021; 8: 700836.
dc.identifier.citedreferencePaulin LM, Diette GB, Blanc PD, Putcha N, Eisner MD, Kanner RE, et al. Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015; 191: 557 – 65.
dc.identifier.citedreferenceDe Matteis S, Jarvis D, Darnton A, Hutchings S, Sadhra S, Fishwick D, et al. The occupations at increased risk of COPD: analysis of lifetime job-histories in the population-based UK Biobank Cohort. Eur Respir J. 2019; 54: 1900186.
dc.identifier.citedreferenceHnizdo E, Sullivan PA, Bang KM, Wagner G. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2002; 156: 738 – 46.
dc.identifier.citedreferenceGuo C, Zhang Z, Lau AKH, Lin CQ, Chuang YC, Chan J, et al. Effect of long-term exposure to fine particulate matter on lung function decline and risk of chronic obstructive pulmonary disease in Taiwan: a longitudinal, cohort study. Lancet Planet Health. 2018; 2: e114 – 25.
dc.identifier.citedreferenceBourbeau J, Doiron D, Biswas S, Smith BM, Benedetti A, Brook JR, et al. Ambient Air Pollution and Dysanapsis: Associations with Lung Function and Chronic Obstructive Pulmonary Disease in the Canadian Cohort Obstructive Lung Disease Study. Am J Respir Crit Care Med. 2022; 206: 44 – 55.
dc.identifier.citedreferenceLi J, Sun S, Tang R, Qiu H, Huang Q, Mason TG, et al. Major air pollutants and risk of COPD exacerbations: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2016; 11: 3079 – 91.
dc.identifier.citedreferenceStoller JK, Aboussouan LS. α1-antitrypsin deficiency. The Lancet. 2005; 365: 2225 – 36.
dc.identifier.citedreferenceBlanco I, Diego I, Bueno P, Pérez-Holanda S, Casas-Maldonado F, Miravitlles M. Prevalence of α(1)-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review. Eur Respir Rev. 2020; 29: 200014.
dc.identifier.citedreferenceStockley RA. Alpha-1 Antitrypsin Deficiency: The Learning Goes On. Am J Respir Crit Care Med. 2020; 202: 6 – 7.
dc.identifier.citedreferenceCho MH, Hobbs BD, Silverman EK. Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder. Lancet Respir Med. 2022; 10: 485 – 96.
dc.identifier.citedreferenceAgusti A, Faner R. Lung function trajectories in health and disease. Lancet Respir Med. 2019; 7: 358 – 64.
dc.identifier.citedreferenceAgustí A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med. 2017; 5: 935 – 45.
dc.identifier.citedreferenceÇolak Y, Nordestgaard BG, Vestbo J, Lange P, Afzal S. Relationship between supernormal lung function and long-term risk of hospitalisations and mortality: a population-based cohort study. Eur Respir J. 2021; 57: 2004055.
dc.identifier.citedreferenceÇolak Y, Nordestgaard BG, Lange P, Vestbo J, Afzal S. Supernormal lung function and risk of COPD: A contemporary population-based cohort study. EClinicalMedicine. 2021; 37: 100974 – 4.
dc.identifier.citedreferenceLawlor DA, Ebrahim S, Davey Smith G. Association of birth weight with adult lung function: findings from the British Women’s Heart and Health Study and a meta-analysis. Thorax. 2005; 60: 851 – 8.
dc.identifier.citedreferenceGreen M, Mead J, Turner JM. Variability of maximum expiratory flow-volume curves. J Appl Physiol. 1974; 37: 67 – 74.
dc.identifier.citedreferenceIto K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest. 2009; 135: 173 – 80.
dc.identifier.citedreferenceMartin TR, Feldman HA, Fredberg JJ, Castile RG, Mead J, Wohl ME. Relationship between maximal expiratory flows and lung volumes in growing humans. J Appl Physiol (1985). 1988; 65: 822 – 8.
dc.identifier.citedreferenceRawlins EL, Okubo T, Xue Y, Brass DM, Auten RL, Hasegawa H, et al. The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell. 2009; 4: 525 – 34.
dc.identifier.citedreferenceSmith BM, Kirby M, Hoffman EA, Kronmal RA, Aaron SD, Allen NB, et al. Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. JAMA. 2020; 323: 2268 – 80.
dc.identifier.citedreferenceDharmage SC, Bui DS, Walters EH, Lowe AJ, Thompson B, Bowatte G, et al. Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study. Lancet Respir Med. 2022; S2213-2600(22)00364-2.
dc.identifier.citedreferenceBose S, Pascoe C, McEvoy C. Lifetime lung function trajectories and COPD: when the train derails. Lancet Respir Med. 2022; S2213-2600(22)00391-5.
dc.identifier.citedreferenceStern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet. 2007; 370: 758 – 64.
dc.identifier.citedreferenceRegan EA, Lynch DA, Curran-Everett D, Curtis JL, Austin JH, Grenier PA, et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry. JAMA Intern Med. 2015; 175: 1539 – 49.
dc.identifier.citedreferenceLange P, Celli B, Agusti A, Boje Jensen G, Divo M, Faner R, et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. 2015; 373: 111 – 22.
dc.identifier.citedreferenceLandis SH, Muellerova H, Mannino DM, Menezes AM, Han MK, van der Molen T, et al. Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis. 2014; 9: 597 – 611.
dc.identifier.citedreferenceDeMeo DL, Ramagopalan S, Kavati A, Vegesna A, Han MK, Yadao A, et al. Women manifest more severe COPD symptoms across the life course. Int J Chron Obstruct Pulmon Dis. 2018; 13: 3021 – 9.
dc.identifier.citedreferenceTownend J, Minelli C, Mortimer K, Obaseki DO, Al Ghobain M, Cherkaski H, et al. The association between chronic airflow obstruction and poverty in 12 sites of the multinational BOLD study. Eur Respir J. 2017; 49: 1601880.
dc.identifier.citedreferenceGershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet. 2011; 378: 991 – 6.
dc.identifier.citedreferencede Marco R, Accordini S, Marcon A, Cerveri I, Antó JM, Gislason T, et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med. 2011; 183: 891 – 7.
dc.identifier.citedreferenceMcGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, et al. Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. New England Journal of Medicine. 2016; 374: 1842 – 52.
dc.identifier.citedreferenceAllinson JP, Hardy R, Donaldson GC, Shaheen SO, Kuh D, Wedzicha JA. Combined Impact of Smoking and Early Life Exposures on Adult Lung Function Trajectories. Am J Respir Crit Care Med. 2017; 196: 1021 – 30.
dc.identifier.citedreferenceMartínez-García M, Faner R, Oscullo G, la Rosa-Carrillo D, Soler-Cataluña JJ, Ballester M, et al. Chronic Bronchial Infection Is Associated with More Rapid Lung Function Decline in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2022; 19: 1842 – 7.
dc.identifier.citedreferenceFan H, Wu F, Liu J, Zeng W, Zheng S, Tian H, et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ann Transl Med. 2021; 9: 390.
dc.identifier.citedreferenceBigna JJ, Kenne AM, Asangbeh SL, Sibetcheu AT. Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. Lancet Glob Health. 2018; 6: e193 – 202.
dc.identifier.citedreferenceAaron SD, Tan WC, Bourbeau J, Sin DD, Loves RH, MacNeil J, et al. Diagnostic Instability and Reversals of Chronic Obstructive Pulmonary Disease Diagnosis in Individuals with Mild to Moderate Airflow Obstruction. Am J Respir Crit Care Med. 2017; 196: 306 – 14.
dc.identifier.citedreferenceSchermer TR, Robberts B, Crockett AJ, Thoonen BP, Lucas A, Grootens J, et al. Should the diagnosis of COPD be based on a single spirometry test? NPJ Prim Care Respir Med. 2016; 26: 16059.
dc.identifier.citedreferencevan Dijk W, Tan W, Li P, Guo B, Li S, Benedetti A, et al. Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort. Ann Fam Med. 2015; 13: 41 – 8.
dc.identifier.citedreferenceGuder G, Brenner S, Angermann CE, Ertl G, Held M, Sachs AP, et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res. 2012; 13: 13.
dc.identifier.citedreferenceBhatt SP, Balte PP, Schwartz JE, Cassano PA, Couper D, Jacobs DR Jr, et al. Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. JAMA. 2019; 321: 2438 – 47.
dc.identifier.citedreferenceAlbert P, Agusti A, Edwards L, Tal-Singer R, Yates J, Bakke P, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012; 67: 701 – 8.
dc.identifier.citedreferenceHansen JE, Porszasz J. Counterpoint: Is an increase in FEV(1) and/or FVC >/= 12% of control and >/= 200 mL the best way to assess positive bronchodilator response? No. Chest. 2014; 146: 538 – 41.
dc.identifier.citedreferenceAgusti A, Hogg JC. Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019; 381: 1248 – 56.
dc.identifier.citedreferenceZhou Y, Zhong NS, Li X, Chen S, Zheng J, Zhao D, et al. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017; 377: 923 – 35.
dc.identifier.citedreferenceMorla M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti AG. Telomere shortening in smokers with and without COPD. Eur Respir J. 2006; 27: 525 – 8.
dc.identifier.citedreferenceMartinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, et al. At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018; 197: 1540 – 51.
dc.identifier.citedreferenceVogiatzis I, Rochester CL, Spruit MA, Troosters T, Clini EM. Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement. Eur Respir J. 2016; 47: 1336 – 41.
dc.identifier.citedreferenceColak Y, Afzal S, Nordestgaard BG, Lange P, Vestbo J. Importance of Early COPD In Young Adults for Development of Clinical COPD: Findings from the Copenhagen General Population Study. Am J Respir Crit Care Med. 2021; 203: 1245 – 56.
dc.identifier.citedreferenceCosío BG, Pascual-Guardia S, Borras-Santos A, Peces-Barba G, Santos S, Vigil L, et al. Phenotypic characterisation of early COPD: a prospective case–control study. ERJ Open Research. 2020; 6: 47 – 2020.
dc.identifier.citedreferenceSanchez-Salcedo P, Divo M, Casanova C, Pinto-Plata V, de Torres JP, Cote C, et al. Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. Eur Respir J. 2014; 44: 324 – 31.
dc.identifier.citedreferenceHan MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, et al. From GOLD 0 to Pre-COPD. Am J Respir Crit Care Med. 2021; 203: 414 – 23.
dc.identifier.citedreferenceHan MK, Ye W, Wang D, White E, Arjomandi M, Barjaktarevic IZ, et al. Woodruff PG. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. N Engl J Med. 2022; 387: 1173 – 84.
dc.identifier.citedreferenceMartinez FJ, Agusti A, Celli BR, Han MK, Allinson J, Bhatt SP. Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. Am J Respir Crit Care Med. 2022; 205: 275 – 87.
dc.identifier.citedreferenceWan ES, Castaldi PJ, Cho MH, Hokanson JE, Regan EA, Make BJ, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res. 2014; 15: 89.
dc.identifier.citedreferenceWan ES. The Clinical Spectrum of PRISm. Am J Respir Crit Care Med. 2022; 206: 524 – 5.
dc.identifier.citedreferenceStolz D, Mkorombindo T, Schumann DM, Agusti A, Ash SY, Bafadhel M, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022; 400: 921 – 72.
dc.identifier.citedreferenceDivo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186: 155 – 61.
dc.identifier.citedreferenceRodriguez-Roisin R, Rabe K, Vestbo J, Vogelmeier C, Agusti A. GOLD 20th anniversary: a brief history of time. Eur Respir J. 2017; 50: 1700671.
dc.identifier.citedreferenceScioscia G, Blanco I, Arismendi E, Burgos F, Gistau C, Foschino Barbaro MP, et al. Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. Thorax. 2017; 72: 117 – 21.
dc.identifier.citedreferenceHaruna A, Muro S, Nakano Y, Ohara T, Hoshino Y, Ogawa E, et al. CT scan findings of emphysema predict mortality in COPD. Chest. 2010; 138: 635 – 40.
dc.identifier.citedreferenceMartinez-Garcia MA, de la Rosa-Carrillo D, Soler-Cataluna JJ, Catalan-Serra P, Ballester M, Roca Vanaclocha Y, et al. Bronchial Infection and Temporal Evolution of Bronchiectasis in Patients With Chronic Obstructive Pulmonary Disease. Clin Infect Dis. 2021; 72: 403 – 10.
dc.identifier.citedreferenceTeam TNLSTR. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine. 2011; 365: 395 – 409.
dc.identifier.citedreferencede Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. New England Journal of Medicine. 2020; 382: 503 – 13.
dc.identifier.citedreferenceGalban CJ, Han MK, Boes JL, Chughtai KA, Meyer CR, Johnson TD, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med. 2012; 18: 1711 – 5.
dc.identifier.citedreferenceVasilescu DM, Martinez FJ, Marchetti N, Galban CJ, Hatt C, Meldrum CA, et al. Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2019; 200: 575 – 81.
dc.identifier.citedreferenceBhatt SP, Soler X, Wang X, Murray S, Anzueto AR, Beaty TH, et al. Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016; 194: 178 – 84.
dc.identifier.citedreferenceEzponda A, Casanova C, Divo M, Marin-Oto M, Cabrera C, Marin JM, et al. Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort. Respirology. 2022; 27: 286 – 93.
dc.identifier.citedreferenceHalpin DMG, Mahler DA. A Systematic Review of Published Algorithms for Selecting an Inhaled Delivery System in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2022; 19: 1213 – 20.
dc.identifier.citedreferenceMahler DA, Decramer M, D’Urzo A, Worth H, White T, Alagappan VK, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014; 43: 1599 – 609.
dc.identifier.citedreferenceSingh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015; 109: 1312 – 9.
dc.identifier.citedreferenceMaltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019; 20: 238.
dc.identifier.citedreferenceLipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine. 2018; 378: 1671 – 80.
dc.identifier.citedreferenceRabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. New England Journal of Medicine. 2020; 383: 35 – 48.
dc.identifier.citedreferenceReddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med. 2022; 205: 17 – 35.
dc.identifier.citedreferenceAgusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate ST, et al. Treatable Traits: Toward Precision Medicine of Airway Diseases. Eur Respir J. 2016; 47: 410 – 9.
dc.identifier.citedreferenceAgusti A, Rapsomaniki E, Beasley R, Hughes R, Mullerova H, Papi A, et al. Treatable traits in the NOVELTY study. Respirology. 2022; 27: 929 – 40.
dc.identifier.citedreferenceMartinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015; 385: 857–66.
dc.identifier.citedreferenceMartinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE2SPOND). A Randomized Clinical Trial. Am J Respir Crit Care Med. 2016; 194: 559 – 67.
dc.identifier.citedreferenceRabe KF, Calverley PMA, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J. 2017; 50: 1700158.
dc.identifier.citedreferenceAlbert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, et al. Azithromycin for Prevention of Exacerbations of COPD. New England Journal of Medicine. 2011; 365: 689 – 98.
dc.identifier.citedreferenceHan MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of COPD Exacerbation Reduction in Response to Daily Azithromycin Therapy. Am J Respir Crit Care Med. 2014; 189: 1503–8.
dc.identifier.citedreferenceMagnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD. New England Journal of Medicine. 2014; 371: 1285 – 94.
dc.identifier.citedreferenceSiddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015; 192: 523 – 5.
dc.identifier.citedreferencePascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3: 435 – 42.
dc.identifier.citedreferencePapi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. The Lancet. 2018; 391: 1076 – 84.
dc.identifier.citedreferenceVestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017; 389: 1919 – 29.
dc.identifier.citedreferenceAgusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FM, et al. Inhaled corticosteroids in COPD: Friend or foe? Eur Respir J. 2018; 52: 1801219.
dc.identifier.citedreferenceSingh D, Agusti A, Martinez FJ, Papi A, Pavord ID, Wedzicha JA, et al. Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. Am J Respir Crit Care Med. 2022; 206: 17 – 24.
dc.identifier.citedreferenceLandis SH, Suruki R, Hilton E, Compton C, Galwey NW. Stability of Blood Eosinophil Count in Patients with COPD in the UK Clinical Practice Research Datalink. COPD. 2017; 14: 382 – 8.
dc.identifier.citedreferenceOshagbemi MOA, Burden DAM, Braeken MDCW, Henskens DY, Wouters PEFM, Driessen MJHM, Zee DAHM-vd, Vries DFd, Franssen DFME. Stability of Blood Eosinophils in COPD and Controls and the Impact of Gender, Age, Smoking and Baseline Counts. Am J Respir Crit Care Med. 2017; 195: 1402 – 4.
dc.identifier.citedreferenceStolbrink M, Thomson H, Hadfield RM, Ozoh OB, Nantanda R, Jayasooriya S, et al. The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review. Lancet Glob Health. 2022; 10: e1423 – 42.
dc.identifier.citedreferenceMontes de Oca M. Smoking Cessation/Vaccinations. Clin Chest Med. 2020; 41: 495 – 512.
dc.identifier.citedreferencePitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 171: 972 – 7.
dc.identifier.citedreferenceMantoani LC, Rubio N, McKinstry B, MacNee W, Rabinovich RA. Interventions to modify physical activity in patients with COPD: a systematic review. Eur Respir J. 2016; 48: 69 – 81.
dc.identifier.citedreferenceWatz H, Pitta F, Rochester CL, Garcia-Aymerich J, Zuwallack R, Troosters T, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014; 44: 1521 – 37.
dc.identifier.citedreferenceSpielmanns M, Gloeckl R, Jarosch I, Leitl D, Schneeberger T, Boeselt T, et al. Using a smartphone application maintains physical activity following pulmonary rehabilitation in patients with COPD: a randomised controlled trial. Thorax. 2022;thoraxjnl-2021-218338.
dc.identifier.citedreferenceSpruit MA, Singh SJ, Garvey C, Zuwallack R, Nici L, Rochester C, et al. An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2013; 188: e13 – 64.
dc.identifier.citedreferenceGarvey C, Bayles MP, Hamm LF, Hill K, Holland A, Limberg TM, et al. Pulmonary Rehabilitation Exercise Prescription in Chronic Obstructive Pulmonary Disease: Review of Selected Guidelines: an official statement from the American Association of cardiovascular and pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 2016; 36: 75 – 83.
dc.identifier.citedreferenceStone PW, Hickman K, Steiner MC, Roberts CM, Quint JK, Singh SJ. Predictors of Referral to Pulmonary Rehabilitation from UK Primary Care. Int J Chron Obstruct Pulmon Dis. 2020; 15: 2941 – 52.
dc.identifier.citedreferenceCox NS, Dal Corso S, Hansen H, McDonald CF, Hill CJ, Zanaboni P, et al. Telerehabilitation for chronic respiratory disease. Cochrane Database Syst Rev. 2021; 1: Cd013040.
dc.identifier.citedreferenceHouchen-Wolloff L, Steiner MC. Pulmonary rehabilitation at a time of social distancing: prime time for tele-rehabilitation? Thorax. 2020; 75: 446 – 7.
dc.identifier.citedreferenceHolland AE, Malaguti C, Hoffman M, Lahham A, Burge AT, Dowman L, et al. Home-based or remote exercise testing in chronic respiratory disease, during the COVID-19 pandemic and beyond: A rapid review. Chron Respir Dis. 2020; 17: 1479973120952418.
dc.identifier.citedreferenceCelli BR, Fabbri LM, Aaron SD, Agusti A, Brook R, Criner GJ, et al. An Updated Definition and Severity Classification of COPD Exacerbations: The Rome Proposal. Am J Respir Crit Care Med. 2021; 204: 1251 – 8.
dc.identifier.citedreferenceBeghe B, Verduri A, Roca M, Fabbri LM. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J. 2013; 41: 993 – 5.
dc.identifier.citedreferenceSoler-Cataluña J, Miravitlles M, Fernandez-Villar A, Izquierdo J, Garcia-Rivero J, Lopez-Campos J, et al. Exacerbations in COPD: a personalized approach to care. Lancet Respir Med. 2023; S2213-2600(22)00533-1.
dc.identifier.citedreferenceBardsley G, Pilcher J, McKinstry S, Shirtcliffe P, Berry J, Fingleton J, et al. Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. BMC Pulm Med. 2018; 18: 157.
dc.identifier.citedreferenceBarr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ. 2003; 327: 643.
dc.identifier.citedreferenceDuffy N, Walker P, Diamantea F, Calverley PM, Davies L. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax. 2005; 60: 713 – 7.
dc.identifier.citedreferenceDavies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999; 354: 456 – 60.
dc.identifier.citedreferenceMaltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002; 165: 698 – 703.
dc.identifier.citedreferenceAaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, et al. Outpatient Oral Prednisone after Emergency Treatment of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2003; 348: 2618.
dc.identifier.citedreferenceLeuppi JD, Schuetz P, Bingisser R. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: The reduce randomized clinical trial. JAMA. 2013; 309: 2223 – 31.
dc.identifier.citedreferenceSivapalan P, Ingebrigtsen TS, Rasmussen DB, Sorensen R, Rasmussen CM, Jensen CB, et al. COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months. BMJ Open Respir Res. 2019; 6: e000407.
dc.identifier.citedreferencede Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest. 2007; 132: 1741 – 7.
dc.identifier.citedreferenceGunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007; 29: 660 – 7.
dc.identifier.citedreferenceBafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2012; 186: 48 – 55.
dc.identifier.citedreferenceAnthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106: 196 – 204.
dc.identifier.citedreferenceLlor C, Moragas A, Miravitlles M, Mesquita P, Cordoba G. Are short courses of antibiotic therapy as effective as standard courses for COPD exacerbations? A systematic review and meta-analysis. Pulm Pharmacol Ther. 2022; 72: 102111.
dc.identifier.citedreferenceCouturaud F, Bertoletti L, Pastre J, Roy PM, Le Mao R, Gagnadoux F, et al. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. JAMA. 2021; 325: 59 – 68.
dc.identifier.citedreferenceJimenez D, Agusti A, Tabernero E, Jara-Palomares L, Hernando A, Ruiz-Artacho P, et al. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial. JAMA. 2021; 326: 1277 – 85.
dc.identifier.citedreferenceAustin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010; 341: c5462.
dc.identifier.citedreferenceLacasse Y, Thériault S, St-Pierre B, Bernard S, Sériès F, Bernatchez HJ, et al. Oximetry neither to prescribe long-term oxygen therapy nor to screen for severe hypoxaemia. ERJ Open Research. 2021; 7: 272 – 2021.
dc.identifier.citedreferenceSjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. Racial Bias in Pulse Oximetry Measurement. N Engl J Med. 2020; 383: 2477 – 8.
dc.identifier.citedreferenceRoca O, Hernández G, Díaz-Lobato S, Carratalá JM, Gutiérrez RM, Masclans JR. Current evidence for the effectiveness of heated and humidified high flow nasal cannula supportive therapy in adult patients with respiratory failure. Crit Care. 2016; 20: 109.
dc.identifier.citedreferenceFraser JF, Spooner AJ, Dunster KR, Anstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax. 2016; 71: 759 – 61.
dc.identifier.citedreferenceMauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, et al. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2017; 195: 1207 – 15.
dc.identifier.citedreferenceNagata K, Horie T, Chohnabayashi N, Jinta T, Tsugitomi R, Shiraki A, et al. Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Clinical Trial. Am J Respir Crit Care Med. 2022; 206: 1326 – 35.
dc.identifier.citedreferenceOczkowski S, Ergan B, Bos L, Chatwin M, Ferrer M, Gregoretti C, et al. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. Eur Respir J. 2022; 59: 2101574.
dc.identifier.citedreferenceClinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation—a consensus conference report. Chest. 1999; 116: 521 – 34.
dc.identifier.citedreferenceOsadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017; 7: Cd004104.
dc.identifier.citedreferenceSellares J, Ferrer M, Anton A, Loureiro H, Bencosme C, Alonso R, et al. Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial. Eur Respir J. 2017; 50: 1601448.
dc.identifier.citedreferenceChandra D, Stamm JA, Taylor B, Ramos RM, Satterwhite L, Krishnan JA, et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med. 2012; 185: 152 – 9.
dc.identifier.citedreferenceAlqahtani JS, Njoku CM, Bereznicki B, Wimmer BC, Peterson GM, Kinsman L, et al. Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis. Eur Respir Rev. 2020; 29: 190166.
dc.identifier.citedreferenceBenzo R, Vickers K, Novotny PJ, Tucker S, Hoult J, Neuenfeldt P, et al. Health Coaching and Chronic Obstructive Pulmonary Disease Rehospitalization. A Randomized Study. Am J Respir Crit Care Med. 2016; 194: 672 – 80.
dc.identifier.citedreferenceGavish R, Levy A, Dekel OK, Karp E, Maimon N. The Association Between Hospital Readmission and Pulmonologist Follow-up Visits in Patients With COPD. Chest. 2015; 148: 375 – 81.
dc.identifier.citedreferenceOga T, Tsukino M, Hajiro T, Ikeda A, Nishimura K. Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011; 6: 521 – 6.
dc.identifier.citedreferenceSpece LJ, Epler EM, Duan K, Donovan LM, Griffith MF, LaBedz S, et al. Reassessment of Home Oxygen Prescription after Hospitalization for Chronic Obstructive Pulmonary Disease. A Potential Target for Deimplementation. Ann Am Thorac Soc. 2021; 18: 426 – 32.
dc.identifier.citedreferencePuhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011; Cd005305.
dc.identifier.citedreferencePuhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016; 12: Cd005305.
dc.identifier.citedreferenceHoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, Vestbo J, Feenstra TL. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J. 2011; 37: 508 – 15.
dc.identifier.citedreferenceGuo Y, Zhang T, Wang Z, Yu F, Xu Q, Guo W, et al. Body mass index and mortality in chronic obstructive pulmonary disease: A dose-response meta-analysis. Medicine (Baltimore). 2016; 95: e4225.
dc.identifier.citedreferenceSinganayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013; 10: 81 – 9.
dc.identifier.citedreferencePiquet J, Chavaillon JM, David P, Martin F, Blanchon F, Roche N. High-risk patients following hospitalisation for an acute exacerbation of COPD. Eur Respir J. 2013; 42: 946 – 55.
dc.identifier.citedreferenceBeghe B, Clini E, Fabbri L. Chronic respiratory abnormalities in the multi-morbid frail elderly. BRN Reviews. 2017; 3: 247–66.
dc.identifier.citedreferenceDivo MJ, Casanova C, Marin JM, Pinto-Plata VM, de Torres JP, Zulueta JJ, et al. COPD comorbidities network. Eur Respir J. 2015; 46: 640 – 50.
dc.identifier.citedreferenceMannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008; 32: 962 – 9.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
resp14486.pdf
Size:
2.984MB
Format:
PDF
View/Open
Name:
resp14486_am.pdf
Size:
1.552MB
Format:
PDF
View/Open
Name:
resp14486-sup-0001-Supinfo.pdf
Size:
1.264MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.